Study reveals why malaria vaccine only partially protected children, infants

Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing. The researchers found that genetic variability in the surface protein targeted by the RTS,S vaccine likely played a significant role.